Advanced search
Publication Cover
Critical Reviews in Biochemistry and Molecular Biology Latest Articles
Submit an article Journal homepage
835
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Approaching the catalytic mechanism of protein lysine methyltransferases by biochemical and simulation techniques

Philipp SchneeInstitute of Biochemistry and Technical Biochemistry, University of Stuttgart, Stuttgart, GermanyORCID Iconhttps://orcid.org/0000-0002-3731-9352View further author information
ORCID Icon,
Jürgen PleissInstitute of Biochemistry and Technical Biochemistry, University of Stuttgart, Stuttgart, GermanyORCID Iconhttps://orcid.org/0000-0003-1045-8202View further author information
ORCID Icon &
Albert JeltschInstitute of Biochemistry and Technical Biochemistry, University of Stuttgart, Stuttgart, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6113-9290View further author information
ORCID Icon
Received 24 Oct 2023, Accepted 10 Feb 2024, Published online: 07 Mar 2024

References

  • Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, Figeys D. 2008. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics. 7(3):560–572. doi: 10.1074/mcp.M700271-MCP200.
  • Abu-Farha M, Lanouette S, Elisma F, Tremblay V, Butson J, Figeys D, Couture JF. 2011. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. J Mol Cell Biol. 3(5):301–308. doi: 10.1093/jmcb/mjr025.
  • Ahmed H, Duan S, Arrowsmith CH, Barsyte-Lovejoy D, Schapira M. 2016. An Integrative Proteomic Approach Identifies Novel Cellular SMYD2 Substrates. J Proteome Res. 15(6):2052–2059. doi: 10.1021/acs.jproteome.6b00220.
  • Al-Shar’i NA, Alnabulsi SM. 2016. Explaining the autoinhibition of the SMYD enzyme family: A theoretical study. J Mol Graph Model. 68:147–157. doi: 10.1016/j.jmgm.2016.07.001.
  • Al Temimi AHK, Reddy YV, White PB, Guo H, Qian P, Mecinović J. 2017. Lysine Possesses the Optimal Chain Length for Histone Lysine Methyltransferase Catalysis. Sci Rep. 7(1):16148. doi: 10.1038/s41598-017-16128-4.
  • Al Temimi AHK, Tran V, Teeuwen RS, Altunc AJ, Amatdjais-Groenen HIV, White PB, Lenstra DC, Proietti G, Wang Y, Wegert A, et al. 2020. Examining sterically demanding lysine analogs for histone lysine methyltransferase catalysis. Sci Rep. 10(1):3671. doi: 10.1038/s41598-020-60337-3.
  • Al Temimi AHK, Amatdjais-Groenen HIV, Reddy YV, Blaauw RH, Guo H, Qian P, Mecinović J. 2019a. The nucleophilic amino group of lysine is central for histone lysine methyltransferase catalysis. Commun Chem. 2(1) doi: 10.1038/s42004-019-0210-8.
  • Al Temimi AHK, van der Wekken-de Bruijne R, Proietti G, Guo H, Qian P, Mecinović J. 2019b. Gamma-Thialysine versus Lysine: An Insight into the Epigenetic Methylation of Histones. Bioconjug Chem. 30(6):1798–1804. doi: 10.1021/acs.bioconjchem.9b00313.
  • Aljazi MB, Gao Y, Wu Y, He J. 2022. SMYD5 is a histone H3-specific methyltransferase mediating mono-methylation of histone H3 lysine 36 and 37. Biochem Biophys Res Commun. 599:142–147. doi: 10.1016/j.bbrc.2022.02.043.
  • Allis CD, Jenuwein T. 2016. The molecular hallmarks of epigenetic control. Nat Rev Genet. 17(8):487–500. doi: 10.1038/nrg.2016.59.
  • An S, Yeo KJ, Jeon YH, Song JJ. 2011. Crystal structure of the human histone methyltransferase ASH1L catalytic domain and its implications for the regulatory mechanism. J Biol Chem. 286(10):8369–8374. doi: 10.1074/jbc.M110.203380.
  • Anderson CJ, Baird MR, Hsu A, Barbour EH, Koyama Y, Borgnia MJ, McGinty RK. 2019. Structural Basis for Recognition of Ubiquitylated Nucleosome by Dot1L Methyltransferase. Cell Rep. 26(7):1681–1690.e5. e1685. doi: 10.1016/j.celrep.2019.01.058.
  • Armache KJ, Garlick JD, Canzio D, Narlikar GJ, Kingston RE. 2011. Structural basis of silencing: Sir3 BAH domain in complex with a nucleosome at 3.0 Å resolution. Science. 334(6058):977–982. doi: 10.1126/science.1210915.
  • Ayoub A, Park SH, Lee YT, Cho US, Dou Y. 2022. Regulation of MLL1 Methyltransferase Activity in Two Distinct Nucleosome Binding Modes. Biochemistry. 61(1):1–9. doi: 10.1021/acs.biochem.1c00603.
  • Bai Q, Shen Y, Yao X, Wang F, Du Y, Wang Q, Jin N, Hai J, Hu T, Yang J. 2011. Modeling a new water channel that allows SET9 to dimethylate p53. PLoS One. 6(5):e19856. doi: 10.1371/journal.pone.0019856.
  • Bannister AJ, Kouzarides T. 2011. Regulation of chromatin by histone modifications. Cell Res. 21(3):381–395. doi: 10.1038/cr.2011.22.
  • Barbera AJ, Chodaparambil JV, Kelley-Clarke B, Joukov V, Walter JC, Luger K, Kaye KM. 2006. The nucleosomal surface as a docking station for Kaposi’s sarcoma herpesvirus LANA. Science. 311(5762):856–861. doi: 10.1126/science.1120541.
  • Basavapathruni A, Jin L, Daigle SR, Majer CRA, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, Scott MP, et al. 2012. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des. 80(6):971–980. doi: 10.1111/cbdd.12050.
  • Basta J, Rauchman M. 2015. The nucleosome remodeling and deacetylase complex in development and disease. Transl Res. 165(1):36–47. doi: 10.1016/j.trsl.2014.05.003.
  • Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, et al. 2013. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 110(45):18250–18255. doi: 10.1073/pnas.1314608110.
  • Bennett RL, Swaroop A, Troche C, Licht JD. 2017. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. Cold Spring Harb Perspect Med. 7(6):a026708. doi: 10.1101/cshperspect.a026708.
  • Bhat KP, Ümit Kaniskan H, Jin J, Gozani O. 2021. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 20(4):265–286. doi: 10.1038/s41573-020-00108-x.
  • Biggar KK, Li SSC. 2015. Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol Cell Biol. 16(1):5–17. doi: 10.1038/nrm3915.
  • Blanco-Esperguez K, Tunon I, Kastner J, Mendizabal F, Miranda-Rojas S. 2022. Unraveling the Role of the Tyrosine Tetrad from the Binding Site of the Epigenetic Writer MLL3 in the Catalytic Mechanism and Methylation Multiplicity. Int J Mol Sci. 23(18)
  • Bochyńska A, Lüscher-Firzlaff J, Lüscher B. 2018. Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin. Cells. 7(3):17. doi: 10.3390/cells7030017.
  • Bock I, Kudithipudi S, Tamas R, Kungulovski G, Dhayalan A, Jeltsch A. 2011. Application of Celluspots peptide arrays for the analysis of the binding specificity of epigenetic reading domains to modified histone tails. BMC Biochem. 12(1):48. doi: 10.1186/1471-2091-12-48.
  • Boehm D, Lam V, Schnolzer M, Ott M. 2023. The lysine methyltransferase SMYD5 amplifies HIV-1 transcription and is post-transcriptionally upregulated by Tat and USP11. Cell Rep. 42(3):112234. doi: 10.1016/j.celrep.2023.112234.
  • Boriack-Sjodin PA, Swinger KK. 2016. Protein Methyltransferases: A Distinct, Diverse, and Dynamic Family of Enzymes. Biochemistry. 55(11):1557–1569. doi: 10.1021/acs.biochem.5b01129.
  • Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, et al. 2015. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 27(4):589–602. doi: 10.1016/j.ccell.2015.02.016.
  • Bottino C, Peserico A, Simone C, Caretti G. 2020. SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways. Cancers (Basel). 12(1):142. doi: 10.3390/cancers12010142.
  • Bramley GA, Beynon OT, Stishenko PV, Logsdail AJ. 2023. The application of QM/MM simulations in heterogeneous catalysis. Phys Chem Chem Phys. 25(9):6562–6585. doi: 10.1039/d2cp04537k.
  • Briggs SD, Xiao T, Sun ZW, Caldwell JA, Shabanowitz J, Hunt DF, Allis CD, Strahl BD. 2002. Gene silencing: trans-histone regulatory pathway in chromatin. Nature. 418(6897):498–498. doi: 10.1038/nature00970.
  • Bussi G, Laio A. 2020. Using metadynamics to explore complex free-energy landscapes. Nat Rev Phys. 2(4):200–212. doi: 10.1038/s42254-020-0153-0.
  • Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, et al. 2014. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell. 53(2):247–261. doi: 10.1016/j.molcel.2013.12.001.
  • Cao Q, Wang X, Zhao M, Yang R, Malik R, Qiao Y, Poliakov A, Yocum AK, Li Y, Chen W, et al. 2014. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 5(1):3127. doi: 10.1038/ncomms4127.
  • Chandramouli B, Chillemi G. 2016. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3. J Chem Inf Model. 56(12):2467–2475. doi: 10.1021/acs.jcim.6b00652.
  • Chandramouli B, Melino G, Chillemi G. 2019. Smyd2 conformational changes in response to p53 binding: role of the C-terminal domain. Mol Oncol. 13(6):1450–1461. doi: 10.1002/1878-0261.12502.
  • Chandramouli B, Silvestri V, Scarno M, Ottini L, Chillemi G. 2016. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from mu-second molecular dynamics simulations. Biochim Biophys Acta. 1860(7):1466–1474. doi: 10.1016/j.bbagen.2016.04.006.
  • Chandrasekharan MB, Huang F, Sun ZW. 2010. Histone H2B ubiquitination and beyond: Regulation of nucleosome stability, chromatin dynamics and the trans-histone H3 methylation. Epigenetics. 5(6):460–468. doi: 10.4161/epi.5.6.12314.
  • Chen J, Park HJ. 2019. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor. ACS Chem Biol. 14(5):873–881. doi: 10.1021/acschembio.8b00933.
  • Chen S, Kapilashrami K, Senevirathne C, Wang Z, Wang J, Linscott JA, Luo M. 2019. Substrate-Differentiated Transition States of SET7/9-Catalyzed Lysine Methylation. J Am Chem Soc. 141(20):8064–8067. doi: 10.1021/jacs.9b02553.
  • Chen S, Li L, Chen Y, Hu J, Liu J, Liu YC, Liu R, Zhang Y, Meng F, Zhu K, et al. 2016. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays. J Chem Inf Model. 56(3):527–534. doi: 10.1021/acs.jcim.5b00738.
  • Chen Z, Zhang Y. 2020. Role of Mammalian DNA Methyltransferases in Development. Annu Rev Biochem. 89(1):135–158. doi: 10.1146/annurev-biochem-103019-102815.
  • Cheng X, Collins RE, Zhang X. 2005. Structural and sequence motifs of protein (histone) methylation enzymes. Annu Rev Biophys Biomol Struct. 34(1):267–294. doi: 10.1146/annurev.biophys.34.040204.144452.
  • Chmiela S, Sauceda HE, Müller K-R, Tkatchenko A. 2018. Towards exact molecular dynamics simulations with machine-learned force fields. Nat Commun. 9(1):3887. doi: 10.1038/s41467-018-06169-2.
  • Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. 2014. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 15(8):536–550. doi: 10.1038/nrm3841.
  • Chu Y, Sun L, Zhong S. 2015. How Y357F, Y276F mutants affect the methylation activity of PRDM9: QM/MM MD and free energy simulations. J Mol Model. 21(5):125. doi: 10.1007/s00894-015-2673-6.
  • Chu Y, Xu Q, Guo H. 2010. Understanding Energetic Origins of Product Specificity of SET8 from QM/MM Free Energy Simulations: What Causes the Stop of Methyl Addition during Histone Lysine Methylation? J Chem Theory Comput. 6(4):1380–1389. doi: 10.1021/ct9006458.
  • Chu Y, Yao J, Guo H. 2012. QM/MM MD and free energy simulations of G9a-like protein (GLP) and its mutants: understanding the factors that determine the product specificity. PLoS One. 7(5):e37674. doi: 10.1371/journal.pone.0037674.
  • Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, et al. 2004. Regulation of p53 activity through lysine methylation. Nature. 432(7015):353–360. doi: 10.1038/nature03117.
  • Clarke SG. 2013. Protein methylation at the surface and buried deep: thinking outside the histone box. Trends Biochem Sci. 38(5):243–252. doi: 10.1016/j.tibs.2013.02.004.
  • Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, Chluba J, Langsley G, Weitzman JB. 2012. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 72(3):810–820. doi: 10.1158/0008-5472.CAN-11-1052.
  • Collins RE, Tachibana M, Tamaru H, Smith KM, Jia D, Zhang X, Selker EU, Shinkai Y, Cheng X. 2005. In vitro and in vivo analyses of a Phe/Tyr switch controlling product specificity of histone lysine methyltransferases. J Biol Chem. 280(7):5563–5570. doi: 10.1074/jbc.M410483200.
  • Copeland RA. 2018. Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. Philos Trans R Soc Lond B Biol Sci. 373(1748):20170080. doi: 10.1098/rstb.2017.0080.
  • Copeland RA, Solomon ME, Richon VM. 2009. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 8(9):724–732. doi: 10.1038/nrd2974.
  • Cornett EM, Ferry L, Defossez PA, Rothbart SB. 2019. Lysine Methylation Regulators Moonlighting outside the Epigenome. Mol Cell. 75(6):1092–1101. doi: 10.1016/j.molcel.2019.08.026.
  • Cortopassi WA, Kumar K, Duarte F, Pimentel AS, Paton RS. 2016. Mechanisms of histone lysine-modifying enzymes: A computational perspective on the role of the protein environment. J Mol Graph Model. 67:69–84. doi: 10.1016/j.jmgm.2016.04.011.
  • Couture JF, Collazo E, Brunzelle JS, Trievel RC. 2005. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev. 19(12):1455–1465. doi: 10.1101/gad.1318405.
  • Couture JF, Collazo E, Hauk G, Trievel RC. 2006. Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol. 13(2):140–146. doi: 10.1038/nsmb1045.
  • Couture JF, Dirk LM, Brunzelle JS, Houtz RL, Trievel RC. 2008. Structural origins for the product specificity of SET domain protein methyltransferases. Proc Natl Acad Sci U S A. 105(52):20659–20664. doi: 10.1073/pnas.0806712105.
  • Dasetty S, Meza-Morales PJ, Getman RB, Sarupria S. 2019. Simulations of interfacial processes: recent advances in force field development. Curr Opin Chem Eng. 23:138–145. doi: 10.1016/j.coche.2019.04.003.
  • Davydova E, Ho AYY, Malecki J, Moen A, Enserink JM, Jakobsson ME, Loenarz C, Falnes PO. 2014. Identification and characterization of a novel evolutionarily conserved lysine-specific methyltransferase targeting eukaryotic translation elongation factor 2 (eEF2). J Biol Chem. 289(44):30499–30510. doi: 10.1074/jbc.M114.601658.
  • Del Rizzo PA, Couture JF, Dirk LM, Strunk BS, Roiko MS, Brunzelle JS, Houtz RL, Trievel RC. 2010. SET7/9 catalytic mutants reveal the role of active site water molecules in lysine multiple methylation. J Biol Chem. 285(41):31849–31858. doi: 10.1074/jbc.M110.114587.
  • Del Rizzo PA, Trievel RC. 2011. Substrate and product specificities of SET domain methyltransferases. Epigenetics. 6(9):1059–1067. doi: 10.4161/epi.6.9.16069.
  • Dhayalan A, Kudithipudi S, Rathert P, Jeltsch A. 2011. Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chem Biol. 18(1):111–120. doi: 10.1016/j.chembiol.2010.11.014.
  • Di Blasi R, Blyuss O, Timms JF, Conole D, Ceroni F, Whitwell HJ. 2021. Non-Histone Protein Methylation: Biological Significance and Bioengineering Potential. ACS Chem Biol. 16(2):238–250. doi: 10.1021/acschembio.0c00771.
  • Di Zazzo E, De Rosa C, Abbondanza C, Moncharmont B. 2013. PRDM Proteins: Molecular Mechanisms in Signal Transduction and Transcriptional Regulation. Biology. 2(1):107–141. doi: 10.3390/biology2010107.
  • DiFiore JV, Ptacek TS, Wang Y, Li B, Simon JM, Strahl BD. 2020. Unique and Shared Roles for Histone H3K36 Methylation States in Transcription Regulation Functions. Cell Rep. 31(10):107751. doi: 10.1016/j.celrep.2020.107751.
  • Douglas J, Hanks S, Temple IK, Davies S, Murray A, Upadhyaya M, Tomkins S, Hughes HE, Cole TR, Rahman N. 2003. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am J Hum Genet. 72(1):132–143. doi: 10.1086/345647.
  • Eastman P, Pande VS. 2010. OpenMM: A Hardware Independent Framework for Molecular Simulations. Comput Sci Eng. 12(4):34–39. doi: 10.1109/MCSE.2010.27.
  • Eastman P, Swails J, Chodera JD, McGibbon RT, Zhao Y, Beauchamp KA, Wang LP, Simmonett AC, Harrigan MP, Stern CD, et al. 2017. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput Biol. 13(7):e1005659. doi: 10.1371/journal.pcbi.1005659.
  • Enchev RI, Schulman BA, Peter M. 2015. Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 16(1):30–44. doi: 10.1038/nrm3919.
  • Ernst P, Vakoc CR. 2012. WRAD: enabler of the SET1-family of H3K4 methyltransferases. Brief Funct Genomics. 11(3):217–226. doi: 10.1093/bfgp/els017.
  • Eskeland R, Czermin B, Boeke J, Bonaldi T, Regula JT, Imhof A. 2004. The N-Terminus of Drosophila SU(VAR)3 − 9 Mediates Dimerization and Regulates Its Methyltransferase Activity. Biochemistry. 43(12):3740–3749. doi: 10.1021/bi035964s.
  • Fabini E, Talibov VO, Mihalic F, Naldi M, Bartolini M, Bertucci C, Del Rio A, Danielson UH. 2019. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3. Biochemistry. 58(35):3634–3645. doi: 10.1021/acs.biochem.9b00420.
  • Falnes PØ, Jakobsson ME, Davydova E, Ho A, Małecki J. 2016. Protein lysine methylation by seven-β-strand methyltransferases. Biochem J. 473(14):1995–2009. doi: 10.1042/BCJ20160117.
  • Falnes PØ, Małecki JM, Herrera MC, Bengtsen M, Davydova E. 2023. Human seven-beta-strand (METTL) methyltransferases - conquering the universe of protein lysine methylation. J Biol Chem. 299(6):104661. doi: 10.1016/j.jbc.2023.104661.
  • Fang D, Gan H, Lee J-H, Han J, Wang Z, Riester SM, Jin L, Chen J, Zhou H, Wang J, et al. 2016. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science. 352(6291):1344–1348. doi: 10.1126/science.aae0065.
  • Fang J, Feng Q, Ketel CS, Wang H, Cao R, Xia L, Erdjument-Bromage H, Tempst P, Simon JA, Zhang Y. 2002. Purification and Functional Characterization of SET8, a Nucleosomal Histone H4-Lysine 20-Specific Methyltransferase. Curr Biol. 12(13):1086–1099. doi: 10.1016/s0960-9822(02)00924-7.
  • Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, Zhang Y. 2002. Methylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain. Curr Biol. 12(12):1052–1058. doi: 10.1016/s0960-9822(02)00901-6.
  • Feoli A, Viviano M, Cipriano A, Milite C, Castellano S, Sbardella G. 2022. Lysine methyltransferase inhibitors: where we are now. RSC Chem Biol. 3(4):359–406. doi: 10.1039/d1cb00196e.
  • Ferguson AD, Larsen NA, Howard T, Pollard H, Green I, Grande C, Cheung T, Garcia-Arenas R, Cowen S, Wu J, et al. 2011. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 19(9):1262–1273. doi: 10.1016/j.str.2011.06.011.
  • Fierz B, Chatterjee C, McGinty RK, Bar-Dagan M, Raleigh DP, Muir TW. 2011. Histone H2B ubiquitylation disrupts local and higher-order chromatin compaction. Nat Chem Biol. 7(2):113–119. doi: 10.1038/nchembio.501.
  • Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A. 2018. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds. Chem Rec. 18(12):1818–1832. doi: 10.1002/tcr.201800091.
  • Flores-León CD, Colorado-Pablo LF, Santos-Contreras MÁ, Aguayo-Ortiz R. 2023. Determination of nucleoside DOT1L inhibitors’ residence times by τRAMD simulations. Front Drug Discov. 2 doi: 10.3389/fddsv.2022.1083198.
  • Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S, et al. 2011. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One. 6(7):e22290. doi: 10.1371/journal.pone.0022290.
  • Frederiks F, Tzouros M, Oudgenoeg G, van Welsem T, Fornerod M, Krijgsveld J, van Leeuwen F. 2008. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat Struct Mol Biol. 15(6):550–557. doi: 10.1038/nsmb.1432.
  • Fu W, Liu N, Qiao Q, Wang M, Min J, Zhu B, Xu RM, Yang N. 2016. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase. J Biol Chem. 291(17):9173–9180. doi: 10.1074/jbc.M115.709832.
  • Gathiaka S, Boykin B, Cáceres T, Hevel JM, Acevedo O. 2016. Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics. Bioorg Med Chem. 24(20):4949–4960. doi: 10.1016/j.bmc.2016.08.009.
  • Ghoneim M, Fuchs HA, Musselman CA. 2021. Histone Tail Conformations: A Fuzzy Affair with DNA. Trends Biochem Sci. 46(7):564–578. doi: 10.1016/j.tibs.2020.12.012.
  • Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, et al. 2015. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-terminal leukemia. Nat Chem Biol. 11(8):571–578. doi: 10.1038/nchembio.1859.
  • Grimsley GR, Scholtz JM, Pace CN. 2009. A summary of the measured pK values of the ionizable groups in folded proteins. Protein Sci. 18(1):247–251. doi: 10.1002/pro.19.
  • Groenhof G. 2013. Introduction to QM/MM simulations. Methods Mol Biol. 924:43–66.
  • Guo H, Guo H. 2007. Mechanism of histone methylation catalyzed by protein lysine methyltransferase SET7/9 and origin of product specificity. Proc Natl Acad Sci U S A. 104(21):8797–8802. doi: 10.1073/pnas.0702981104.
  • Ha K, Anand P, Lee JA, Jones JR, Kim CA, Bertola DR, Labonne JD, Layman LC, Wenzel W, Kim HG. 2016. Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort. Genes (Basel).). 7(11):96. doi: 10.3390/genes7110096.
  • Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. 2004. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 6(8):731–740. doi: 10.1038/ncb1151.
  • Hamey JJ, Wienert B, Quinlan KGR, Wilkins MR. 2017. METTL21B Is a Novel Human Lysine Methyltransferase of Translation Elongation Factor 1A: Discovery by CRISPR/Cas9 Knockout. Mol Cell Proteomics. 16(12):2229–2242. doi: 10.1074/mcp.M116.066308.
  • He Y, Selvaraju S, Curtin ML, Jakob CG, Zhu H, Comess KM, Shaw B, The J, Lima-Fernandes E, Szewczyk MM, et al. 2017. The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol. 13(4):389–395. doi: 10.1038/nchembio.2306.
  • Hollingsworth SA, Dror RO. 2018. Molecular Dynamics Simulation for All. Neuron. 99(6):1129–1143. doi: 10.1016/j.neuron.2018.08.011.
  • Holt MT, David Y, Pollock S, Tang Z, Jeon J, Kim J, Roeder RG, Muir TW. 2015. Identification of a functional hotspot on ubiquitin required for stimulation of methyltransferase activity on chromatin. Proc Natl Acad Sci U S A. 112(33):10365–10370. doi: 10.1073/pnas.1504483112.
  • Horowitz S, Adhikari U, Dirk LM, Del Rizzo PA, Mehl RA, Houtz RL, Al-Hashimi HM, Scheiner S, Trievel RC. 2014. Manipulating unconventional CH-based hydrogen bonding in a methyltransferase via noncanonical amino acid mutagenesis. ACS Chem Biol. 9(8):1692–1697. doi: 10.1021/cb5001185.
  • Horowitz S, Yesselman JD, Al-Hashimi HM, Trievel RC. 2011. Direct evidence for methyl group coordination by carbon-oxygen hydrogen bonds in the lysine methyltransferase SET7/9. J Biol Chem. 286(21):18658–18663. doi: 10.1074/jbc.M111.232876.
  • Hospital A, Goñi JR, Orozco M, Gelpí JL. 2015. Molecular dynamics simulations: advances and applications. Adv Appl Bioinform Chem. 8:37–47. doi: 10.2147/AABC.S70333.
  • Hsu PL, Shi H, Leonen C, Kang J, Chatterjee C, Zheng N. 2019. Structural Basis of H2B Ubiquitination-Dependent H3K4 Methylation by COMPASS. Mol Cell. 76(5):712–723.e4. e714. doi: 10.1016/j.molcel.2019.10.013.
  • Hu P, Wang S, Zhang Y. 2008. How Do SET-Domain Protein Lysine Methyltransferases Achieve the Methylation State Specificity? Revisited by Ab Initio QM/MM Molecular Dynamics Simulations. J Am Chem Soc. 130(12):3806–3813. doi: 10.1021/ja075896n.
  • Hu P, Zhang Y. 2006. Catalytic Mechanism and Product Specificity of the Histone Lysine Methyltransferase SET7/9: An ab Initio QM/MM-FE Study with Multiple Initial Structures. J Am Chem Soc. 128(4):1272–1278. doi: 10.1021/ja056153+.
  • Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL. 2006. Repression of p53 activity by Smyd2-mediated methylation. Nature. 444(7119):629–632. doi: 10.1038/nature05287.
  • Huertas J, Schöler HR, Cojocaru V. 2021. Histone tails cooperate to control the breathing of genomic nucleosomes. PLoS Comput Biol. 17(6):e1009013. doi: 10.1371/journal.pcbi.1009013.
  • Husmann D, Gozani O. 2019. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 26(10):880–889. doi: 10.1038/s41594-019-0298-7.
  • Ibáñez G, McBean JL, Astudillo YM, Luo M. 2010. An enzyme-coupled ultrasensitive luminescence assay for protein methyltransferases. Anal Biochem. 401(2):203–210. doi: 10.1016/j.ab.2010.03.010.
  • Iglesias N, Currie MA, Jih G, Paulo JA, Siuti N, Kalocsay M, Gygi SP, Moazed D. 2018. Automethylation-induced conformational switch in Clr4 (Suv39h) maintains epigenetic stability. Nature. 560(7719):504–508. doi: 10.1038/s41586-018-0398-2.
  • Jacobs SA, Harp JM, Devarakonda S, Kim Y, Rastinejad F, Khorasanizadeh S. 2002. The active site of the SET domain is constructed on a knot. Nat Struct Biol. 9(11):833–838. doi: 10.1038/nsb861.
  • Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang H-eC, Taylor JE, Hu M, Englund NP, et al. 2013. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet. 45(11):1386–1391. doi: 10.1038/ng.2777.
  • Jakobsson ME. 2021a. Enzymology and significance of protein histidine methylation. J Biol Chem. 297(4):101130. doi: 10.1016/j.jbc.2021.101130.
  • Jakobsson ME. 2021b. Structure, Activity and Function of the Dual Protein Lysine and Protein N-Terminal Methyltransferase METTL13. Life (Basel). 11(11)doi: 10.3390/life11111121.
  • Jakobsson ME, Malecki J, Nilges BS, Moen A, Leidel SA, Falnes PO. 2017. Methylation of human eukaryotic elongation factor alpha (eEF1A) by a member of a novel protein lysine methyltransferase family modulates mRNA translation. Nucleic Acids Res. 45(14):8239–8254. doi: 10.1093/nar/gkx432.
  • Jakobsson ME, Małecki JM, Halabelian L, Nilges BS, Pinto R, Kudithipudi S, Munk S, Davydova E, Zuhairi FR, Arrowsmith CH, et al. 2018. The dual methyltransferase METTL13 targets N terminus and Lys55 of eEF1A and modulates codon-specific translation rates. Nat Commun. 9(1):3411. doi: 10.1038/s41467-018-05646-y.
  • Jakobsson ME, Moen A, Bousset L, Egge-Jacobsen W, Kernstock S, Melki R, Falnes PO. 2013. Identification and characterization of a novel human methyltransferase modulating Hsp70 protein function through lysine methylation. J Biol Chem. 288(39):27752–27763. doi: 10.1074/jbc.M113.483248.
  • Jambhekar A, Dhall A, Shi Y. 2019. Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 20(10):625–641. doi: 10.1038/s41580-019-0151-1.
  • Jang S, Kang C, Yang HS, Jung T, Hebert H, Chung KY, Kim SJ, Hohng S, Song JJ. 2019. Structural basis of recognition and destabilization of the histone H2B ubiquitinated nucleosome by the DOT1L histone H3 Lys79 methyltransferase. Genes Dev. 33(11-12):620–625. doi: 10.1101/gad.323790.118.
  • Janson G, Paiardini A. 2021. PyMod 3: a complete suite for structural bioinformatics in PyMOL. Bioinformatics. 37(10):1471–1472. doi: 10.1093/bioinformatics/btaa849.
  • Jarrold J, Davies CC. 2019. PRMTs and Arginine Methylation: Cancer’s Best-Kept Secret? Trends Mol Med. 25(11):993–1009. doi: 10.1016/j.molmed.2019.05.007.
  • Jayaram H, Hoelper D, Jain SU, Cantone N, Lundgren SM, Poy F, Allis CD, Cummings R, Bellon S, Lewis PW. 2016. S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3. Proc Natl Acad Sci U S A. 113(22):6182–6187. doi: 10.1073/pnas.1605523113.
  • Jiang Y, Sirinupong N, Brunzelle J, Yang Z. 2011. Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain. PLoS One. 6(6):e21640. doi: 10.1371/journal.pone.0021640.
  • Jiang Y, Trescott L, Holcomb J, Zhang X, Brunzelle J, Sirinupong N, Shi X, Yang Z. 2014. Structural insights into estrogen receptor alpha methylation by histone methyltransferase SMYD2, a cellular event implicated in estrogen signaling regulation. J Mol Biol. 426(20):3413–3425. doi: 10.1016/j.jmb.2014.02.019.
  • Joshi SY, Deshmukh SA. 2020. A review of advancements in coarse-grained molecular dynamics simulations. Mol Simul. 47(10-11):786–803. doi: 10.1080/08927022.2020.1828583.
  • Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. 2021. Highly accurate protein structure prediction with AlphaFold. Nature. 596(7873):583–589. doi: 10.1038/s41586-021-03819-2.
  • Justin N, Zhang Y, Tarricone C, Martin SR, Chen S, Underwood E, De Marco V, Haire LF, Walker PA, Reinberg D, et al. 2016. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun. 7(1):11316. doi: 10.1038/ncomms11316.
  • Kalashnikova AA, Porter-Goff ME, Muthurajan UM, Luger K, Hansen JC. 2013. The role of the nucleosome acidic patch in modulating higher order chromatin structure. J R Soc Interface. 10(82):20121022. doi: 10.1098/rsif.2012.1022.
  • Kato H, Jiang J, Zhou BR, Rozendaal M, Feng H, Ghirlando R, Xiao TS, Straight AF, Bai Y. 2013. A conserved mechanism for centromeric nucleosome recognition by centromere protein CENP-C. Science. 340(6136):1110–1113. doi: 10.1126/science.1235532.
  • Khella MS, Brohm A, Weirich S, Jeltsch A. 2020. Mechanistic Insights into the Allosteric Regulation of the Clr4 Protein Lysine Methyltransferase by Autoinhibition and Automethylation. Int J Mol Sci. 21(22)
  • Khella MS, Schnee P, Weirich S, Bui T, Bröhm A, Bashtrykov P, Pleiss J, Jeltsch A. 2023. The T1150A cancer mutant of the protein lysine dimethyltransferase NSD2 can introduce H3K36 trimethylation. J Biol Chem. 299(6):104796. doi: 10.1016/j.jbc.2023.104796.
  • Khirsariya P, Pospíšil P, Maier L, Boudný M, Babáš M, Kroutil O, Mráz M, Vácha R, Paruch K. 2022. Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides. J Med Chem. 65(7):5701–5723. doi: 10.1021/acs.jmedchem.1c02228.
  • Kim J, Guermah M, McGinty RK, Lee JS, Tang Z, Milne TA, Shilatifard A, Muir TW, Roeder RG. 2009. RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell. 137(3):459–471. doi: 10.1016/j.cell.2009.02.027.
  • Kim J, Hake SB, Roeder RG. 2005. The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Mol Cell. 20(5):759–770. doi: 10.1016/j.molcel.2005.11.012.
  • Kim J, Kim JA, McGinty RK, Nguyen UT, Muir TW, Allis CD, Roeder RG. 2013. The n-SET domain of Set1 regulates H2B ubiquitylation-dependent H3K4 methylation. Mol Cell. 49(6):1121–1133. doi: 10.1016/j.molcel.2013.01.034.
  • Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, Orkin SH. 2013. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 9(10):643–650. doi: 10.1038/nchembio.1331.
  • Klimpel GR, Fleischman WR. 1984. Spectrographic Representation of Globular Protein Breathing Motions. Science. 223(4632):181–182.
  • Kmiecik S, Gront D, Kolinski M, Wieteska L, Dawid AE, Kolinski A. 2016. Coarse-Grained Protein Models and Their Applications. Chem Rev. 116(14):7898–7936. doi: 10.1021/acs.chemrev.6b00163.
  • Kothapalli N, Camporeale G, Kueh A, Chew YC, Oommen AM, Griffin JB, Zempleni J. 2005. Biological functions of biotinylated histones. J Nutr Biochem. 16(7):446–448. doi: 10.1016/j.jnutbio.2005.03.025.
  • Kudithipudi S, Jeltsch A. 2016. Approaches and Guidelines for the Identification of Novel Substrates of Protein Lysine Methyltransferases. Cell Chem Biol. 23(9):1049–1055. doi: 10.1016/j.chembiol.2016.07.013.
  • Kudithipudi S, Kusevic D, Weirich S, Jeltsch A. 2014. Specificity analysis of protein lysine methyltransferases using SPOT peptide arrays. J Vis Exp. (93):e52203. doi: 10.3791/52203.
  • Kudithipudi S, Lungu C, Rathert P, Happel N, Jeltsch A. 2014. Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1. Chem Biol. 21(2):226–237. doi: 10.1016/j.chembiol.2013.10.016.
  • Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T, Ohashi H, Naritomi K, Tsukahara M, Makita Y, et al. 2002. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet. 30(4):365–366. doi: 10.1038/ng863.
  • Kusevic D, Kudithipudi S, Iglesias N, Moazed D, Jeltsch A. 2017. Clr4 specificity and catalytic activity beyond H3K9 methylation. Biochimie. 135:83–88. doi: 10.1016/j.biochi.2017.01.013.
  • Kwiatkowski S, Drozak J. 2020. Protein Histidine Methylation. Curr Protein Pept Sci. 21(7):675–689. doi: 10.2174/1389203721666200318161330.
  • Kwon M, Park K, Hyun K, Lee JH, Zhou L, Cho YW, Ge K, Skalnik DG, Muir TW, Kim J. 2020. H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes. Nucleic Acids Res. 48(10):5442–5456. doi: 10.1093/nar/gkaa317.
  • Kwon T, Chang JH, Kwak E, Lee CW, Joachimiak A, Kim YC, Lee J, Cho Y. 2003. Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. Embo J. 22(2):292–303. doi: 10.1093/emboj/cdg025.
  • Lacoste N, Utley RT, Hunter JM, Poirier GG, Côte J. 2002. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J Biol Chem. 277(34):30421–30424. doi: 10.1074/jbc.C200366200.
  • Lanouette S, Davey JA, Elisma F, Ning Z, Figeys D, Chica RA, Couture JF. 2015. Discovery of substrates for a SET domain lysine methyltransferase predicted by multistate computational protein design. Structure. 23(1):206–215. doi: 10.1016/j.str.2014.11.004.
  • Lee CH, Yu JR, Kumar S, Jin Y, LeRoy G, Bhanu N, Kaneko S, Garcia BA, Hamilton AD, Reinberg D. 2018. Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. Mol Cell. 70(3):422–434.e6. e426. doi: 10.1016/j.molcel.2018.03.020.
  • Li W, Tian W, Yuan G, Deng P, Sengupta D, Cheng Z, Cao Y, Ren J, Qin Y, Zhou Y, et al. 2021. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature. 590(7846):498–503. doi: 10.1038/s41586-020-03069-8.
  • Li Y, Han J, Zhang Y, Cao F, Liu Z, Li S, Wu J, Hu C, Wang Y, Shuai J, et al. 2016. Structural basis for activity regulation of MLL family methyltransferases. Nature. 530(7591):447–452. doi: 10.1038/nature16952.
  • Li Y, Trojer P, Xu C-F, Cheung P, Kuo A, Drury WJ, Qiao Q, Neubert TA, Xu R-M, Gozani O, et al. 2009. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem. 284(49):34283–34295. doi: 10.1074/jbc.M109.034462.
  • Lindorff-Larsen K, Maragakis P, Piana S, Eastwood MP, Dror RO, Shaw DE. 2012. Systematic validation of protein force fields against experimental data. PLoS One. 7(2):e32131. doi: 10.1371/journal.pone.0032131.
  • Linscott JA, Kapilashrami K, Wang Z, Senevirathne C, Bothwell IR, Blum G, Luo M. 2016. Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8. Proc Natl Acad Sci U S A. 113(52):E8369–E8378.
  • Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, et al. 2019. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell. 176(3):491–504.e21. e421. doi: 10.1016/j.cell.2018.11.038.
  • Liu Y, Chen W, Gaudet J, Cheney MD, Roudaia L, Cierpicki T, Klet RC, Hartman K, Laue TM, Speck NA, et al. 2007. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO’s activity. Cancer Cell. 11(6):483–497. doi: 10.1016/j.ccr.2007.04.010.
  • Liu Y, Zhang Y, Xue H, Cao M, Bai G, Mu Z, Yao Y, Sun S, Fang D, Huang J. 2021. Cryo-EM structure of SETD2/Set2 methyltransferase bound to a nucleosome containing oncohistone mutations. Cell Discov. 7(1):32. doi: 10.1038/s41421-021-00261-6.
  • Lopes PEM, Guvench O, MacKerell AD. 2015. Current Status of Protein Force Fields for Molecular Dynamics Simulations. In: Kukol A, editor. Molecular Modeling of Proteins. New York, NY: Springer New York; p. 47–71.
  • López-López E, Rabal O, Oyarzabal J, Medina-Franco JL. 2020. Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach. J Comput Aided Mol Des. 34(6):659–669. doi: 10.1007/s10822-020-00298-x.
  • Lu-Culligan WJ, Connor LJ, Xie Y, Ekundayo BE, Rose BT, Machyna M, Pintado-Urbanc AP, Zimmer JT, Vock IW, Bhanu NV, et al. 2023. Acetyl-methyllysine marks chromatin at active transcription start sites. Nature. 622(7981):173–179. doi: 10.1038/s41586-023-06565-9.
  • Luo M. 2012. Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem Biol. 7(3):443–463. doi: 10.1021/cb200519y.
  • Luo M. 2015. Inhibitors of protein methyltransferases as chemical tools. Epigenomics. 7(8):1327–1338. doi: 10.2217/epi.15.87.
  • Luo M. 2018. Chemical and Biochemical Perspectives of Protein Lysine Methylation. Chem Rev. 118(14):6656–6705. doi: 10.1021/acs.chemrev.8b00008.
  • Luo M, Wang H, Zou Y, Zhang S, Xiao J, Jiang G, Zhang Y, Lai Y. 2016. Identification of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking screening and molecular dynamics simulation. J Mol Graph Model. 68:128–139. doi: 10.1016/j.jmgm.2016.06.011.
  • Magen S, Magnani R, Haziza S, Hershkovitz E, Houtz R, Cambi F, Parvari R. 2012. Human calmodulin methyltransferase: expression, activity on calmodulin, and Hsp90 dependence. PLoS One. 7(12):e52425. doi: 10.1371/journal.pone.0052425.
  • Makde RD, England JR, Yennawar HP, Tan S. 2010. Structure of RCC1 chromatin factor bound to the nucleosome core particle. Nature. 467(7315):562–566. doi: 10.1038/nature09321.
  • Makowski L, Rodi DJ, Mandava S, Minh DD, Gore DB, Fischetti RF. 2008. Molecular crowding inhibits intramolecular breathing motions in proteins. J Mol Biol. 375(2):529–546. doi: 10.1016/j.jmb.2007.07.075.
  • Malecki J, Aileni VK, Ho AYY, Schwarz J, Moen A, Sorensen V, Nilges BS, Jakobsson ME, Leidel SA, Falnes PO. 2017. The novel lysine specific methyltransferase METTL21B affects mRNA translation through inducible and dynamic methylation of Lys-165 in human eukaryotic elongation factor 1 alpha (eEF1A). Nucleic Acids Res. 45(8):4370–4389.
  • Małecki J, Ho AYY, Moen A, Dahl H-A, Falnes PØ. 2015. Human METTL20 is a mitochondrial lysine methyltransferase that targets the beta subunit of electron transfer flavoprotein (ETFbeta) and modulates its activity. J Biol Chem. 290(1):423–434. doi: 10.1074/jbc.M114.614115.
  • Mariño Pérez L, Ielasi FS, Bessa LM, Maurin D, Kragelj J, Blackledge M, Salvi N, Bouvignies G, Palencia A, Jensen MR. 2022. Visualizing protein breathing motions associated with aromatic ring flipping. Nature. 602(7898):695–700. doi: 10.1038/s41586-022-04417-6.
  • Marouco D, Garabadgiu A, Melino G, Barlev NA. 2013. Lysine-specific modifications of p53: a matter of life and death? Oncotarget. 4(10):1556–1571. doi: 10.18632/oncotarget.1436.
  • Marrink SJ, Tieleman DP. 2013. Perspective on the Martini model. Chem Soc Rev. 42(16):6801–6822. doi: 10.1039/c3cs60093a.
  • Mattiroli F, Sixma TK. 2014. Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways. Nat Struct Mol Biol. 21(4):308–316. doi: 10.1038/nsmb.2792.
  • Mazur PK, Reynoird N, Khatri P, Jansen PWTC, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, et al. 2014. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 510(7504):283–287. doi: 10.1038/nature13320.
  • McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, Smitheman KN, Ott HM, Pappalardi MB, Allen KE, et al. 2012. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A. 109(8):2989–2994. doi: 10.1073/pnas.1116418109.
  • McLean CM, Karemaker ID, van Leeuwen F. 2014. The emerging roles of DOT1L in leukemia and normal development. Leukemia. 28(11):2131–2138. doi: 10.1038/leu.2014.169.
  • Medjkane S, Cock-Rada A, Weitzman JB. 2012. Role of the SMYD3 histone methyltransferase in tumorigenesis: local or global effects? Cell Cycle. 11(10):1865–1865. doi: 10.4161/cc.20415.
  • Meller J. 2001. Molecular Dynamics. Encyclopedia of Life Sciences. Nature Publishing Group.
  • Millán-Zambrano G, Burton A, Bannister AJ, Schneider R. 2022. Histone post-translational modifications—cause and consequence of genome function. Nat Rev Genet. 23(9):563–580. doi: 10.1038/s41576-022-00468-7.
  • Min J, Feng Q, Li Z, Zhang Y, Xu RM. 2003. Structure of the Catalytic Domain of Human DOT1L, a Non-SET Domain Nucleosomal Histone Methyltransferase. Cell. 112(5):711–723. doi: 10.1016/s0092-8674(03)00114-4.
  • Miranda-Rojas S, Blanco-Esperguez K, Tuñón I, Kästner J, Mendizábal F. 2021. Exploration of the Activation Mechanism of the Epigenetic Regulator MLL3: A QM/MM Study. Biomolecules. 11(7):1051. doi: 10.3390/biom11071051.
  • Monticelli L, Tieleman DP. 2013. Force Fields for Classical Molecular Dynamics. In: Monticelli L, Salonen E, editors. Biomolecular Simulations: Methods and Protocols. Totowa, NJ: Humana Press; p. 197–213.
  • Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. 2010. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 42(2):181–185. doi: 10.1038/ng.518.
  • Morishita M, di Luccio E. 2011. Structural insights into the regulation and the recognition of histone marks by the SET domain of NSD1. Biochem Biophys Res Commun. 412(2):214–219. doi: 10.1016/j.bbrc.2011.07.061.
  • Mzoughi S, Tan YX, Low D, Guccione E. 2016. The role of PRDMs in cancer: one family, two sides. Curr Opin Genet Dev. 36:83–91. doi: 10.1016/j.gde.2016.03.009.
  • Nakanishi S, Sanderson BW, Delventhal KM, Bradford WD, Staehling-Hampton K, Shilatifard A. 2008. A comprehensive library of histone mutants identifies nucleosomal residues required for H3K4 methylation. Nat Struct Mol Biol. 15(8):881–888. doi: 10.1038/nsmb.1454.
  • Ng HH, Feng Q, Wang H, Erdjument-Bromage H, Tempst P, Zhang Y, Struhl K. 2002. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev. 16(12):1518–1527. doi: 10.1101/gad.1001502.
  • Ng HH, Xu RM, Zhang Y, Struhl K. 2002. Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem. 277(38):34655–34657. doi: 10.1074/jbc.C200433200.
  • Ng SS, Kavanagh KL, McDonough MA, Butler D, Pilka ES, Lienard BM, Bray JE, Savitsky P, Gileadi O, von Delft F, et al. 2007. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature. 448(7149):87–91. doi: 10.1038/nature05971.
  • Nguyen TQ, Koh S, Kwon J, Jang S, Kang W, Yang JK. 2023. Structural basis for recognition and methylation of p97 by METTL21D, a valosin-containing protein lysine methyltransferase. iScience. 26(7):107222. doi: 10.1016/j.isci.2023.107222.
  • Olsen JB, Cao XJ, Han B, Chen LH, Horvath A, Richardson TI, Campbell RM, Garcia BA, Nguyen H. 2016. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics. Mol Cell Proteomics. 15(3):892–905. doi: 10.1074/mcp.M115.053280.
  • Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, Carpenter Z, Allegretta M, Okot-Kotber CI, Patel JP, Melnick A, et al. 2014. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 28(1):198–201. doi: 10.1038/leu.2013.204.
  • Park S, Schulten K. 2004. Calculating potentials of mean force from steered molecular dynamics simulations. J Chem Phys. 120(13):5946–5961. doi: 10.1063/1.1651473.
  • Park SH, Ayoub A, Lee YT, Xu J, Kim H, Zheng W, Zhang B, Sha L, An S, Zhang Y, et al. 2019. Cryo-EM structure of the human MLL1 core complex bound to the nucleosome. Nat Commun. 10(1):5540. doi: 10.1038/s41467-019-13550-2.
  • Patel A, Dharmarajan V, Vought VE, Cosgrove MS. 2009. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. J Biol Chem. 284(36):24242–24256. doi: 10.1074/jbc.M109.014498.
  • Patel A, Vought VE, Dharmarajan V, Cosgrove MS. 2011. A novel non-SET domain multi-subunit methyltransferase required for sequential nucleosomal histone H3 methylation by the mixed lineage leukemia protein-1 (MLL1) core complex. J Biol Chem. 286(5):3359–3369. doi: 10.1074/jbc.M110.174524.
  • Patel A, Vought VE, Swatkoski S, Viggiano S, Howard B, Dharmarajan V, Monteith KE, Kupakuwana G, Namitz KE, Shinsky SA, et al. 2014. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation. J Biol Chem. 289(2):868–884. doi: 10.1074/jbc.M113.501064.
  • Patel DJ, Wang Z. 2013. Readout of epigenetic modifications. Annu Rev Biochem. 82(1):81–118. doi: 10.1146/annurev-biochem-072711-165700.
  • Patnaik D, Chin HG, Estève P-O, Benner J, Jacobsen SE, Pradhan S. 2004. Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase. J Biol Chem. 279(51):53248–53258. doi: 10.1074/jbc.M409604200.
  • Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, et al. 2023. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 615(7954):913–919. doi: 10.1038/s41586-023-05755-9.
  • Petrossian TC, Clarke SG. 2011. Uncovering the human methyltransferasome. Mol Cell Proteomics. 10(1):M110. 000976.
  • Potoyan DA, Papoian GA. 2011. Energy landscape analyses of disordered histone tails reveal special organization of their conformational dynamics. J Am Chem Soc. 133(19):7405–7415. doi: 10.1021/ja1111964.
  • Poulard C, Noureddine LM, Pruvost L, Le Romancer M. 2021. Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a. Life (Basel). 11(10) doi: 10.3390/life11101082.
  • Poulin MB, Schneck JL, Matico RE, Hou W, McDevitt PJ, Holbert M, Schramm VL. 2016. Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2. J Am Chem Soc. 138(21):6699–6702. doi: 10.1021/jacs.6b01612.
  • Poulin MB, Schneck JL, Matico RE, McDevitt PJ, Huddleston MJ, Hou W, Johnson NW, Thrall SH, Meek TD, Schramm VL. 2016. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36. Proc Natl Acad Sci U S A. 113(5):1197–1201. doi: 10.1073/pnas.1521036113.
  • Qian C, Zhou MM. 2006. SET domain protein lysine methyltransferases: Structure, specificity and catalysis. Cell Mol Life Sci. 63(23):2755–2763. doi: 10.1007/s00018-006-6274-5.
  • Qian P, Guo H, Wang L, Guo H. 2017. QM/MM Investigation of Substrate and Product Specificities of Suv4-20h2: How Does This Enzyme Generate Dimethylated H4K20 from Monomethylated Substrate? J Chem Theory Comput. 13(6):2977–2986. doi: 10.1021/acs.jctc.7b00069.
  • Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, Xu RM. 2011. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem. 286(10):8361–8368. doi: 10.1074/jbc.M110.204115.
  • Rahman S, Hoffmann NA, Worden EJ, Smith ML, Namitz KEW, Knutson BA, Cosgrove MS, Wolberger C. 2022. Multistate structures of the MLL1-WRAD complex bound to H2B-ubiquitinated nucleosome. Proc Natl Acad Sci U S A. 119(38):e2205691119.
  • Raj U, Kumar H, Gupta S, Varadwaj PK. 2015. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study. Asian Pac J Cancer Prev. 16(9):3817–3825. doi: 10.7314/apjcp.2015.16.9.3817.
  • Rao RC, Dou Y. 2015. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 15(6):334–346. doi: 10.1038/nrc3929.
  • Rathert P, Dhayalan A, Ma H, Jeltsch A. 2008. Specificity of protein lysine methyltransferases and methods for detection of lysine methylation of non-histone proteins. Mol Biosyst. 4(12):1186–1190. doi: 10.1039/b811673c.
  • Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, Komatsu Y, Shinkai Y, Cheng X, Jeltsch A. 2008. Protein lysine methyltransferase G9a acts on non-histone targets. Nat Chem Biol. 4(6):344–346. doi: 10.1038/nchembio.88.
  • Rhein VF, Carroll J, He J, Ding S, Fearnley IM, Walker JE. 2014. Human METTL20 methylates lysine residues adjacent to the recognition loop of the electron transfer flavoprotein in mitochondria. J Biol Chem. 289(35):24640–24651. doi: 10.1074/jbc.M114.580464.
  • Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, Jerva LF, Scott MP, Copeland RA. 2011. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des. 78(2):199–210. doi: 10.1111/j.1747-0285.2011.01135.x.
  • Rogawski DS, Ndoj J, Cho HJ, Maillard I, Grembecka J, Cierpicki T. 2015. Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase. Biochemistry. 54(35):5401–5413. doi: 10.1021/acs.biochem.5b00697.
  • Sabari BR, Zhang D, Allis CD, Zhao Y. 2017. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 18(2):90–101. doi: 10.1038/nrm.2016.140.
  • Saddic LA, West LE, Aslanian A, Yates JR, Rubin SM, Gozani O, Sage J. 2010. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 285(48):37733–37740. doi: 10.1074/jbc.M110.137612.
  • Sarno F, Nebbioso A, Altucci L. 2020. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. Epigenetics. 15(5):439–453. doi: 10.1080/15592294.2019.1699991.
  • Sato K, Kumar A, Hamada K, Okada C, Oguni A, Machiyama A, Sakuraba S, Nishizawa T, Nureki O, Kono H, et al. 2021. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2. Nat Commun. 12(1):6605. doi: 10.1038/s41467-021-26913-5.
  • Saugier-Veber P, Bonnet C, Afenjar A, Drouin-Garraud V, Coubes C, Fehrenbach S, Holder-Espinasse M, Roume J, Malan V, Portnoi MF, et al. 2007. Heterogeneity of NSD1 alterations in 116 patients with Sotos syndrome. Hum Mutat. 28(11):1098–1107. doi: 10.1002/humu.20568.
  • Schapira M. 2016. Chemical Inhibition of Protein Methyltransferases. Cell Chem Biol. 23(9):1067–1076. doi: 10.1016/j.chembiol.2016.07.014.
  • Schnee P, Choudalakis M, Weirich S, Khella MS, Carvalho H, Pleiss J, Jeltsch A. 2022. Mechanistic basis of the increased methylation activity of the SETD2 protein lysine methyltransferase towards a designed super-substrate peptide. Commun Chem. 5(1):139. doi: 10.1038/s42004-022-00753-w.
  • Schuhmacher MK, Beldar S, Khella MS, Bröhm A, Ludwig J, Tempel W, Weirich S, Min J, Jeltsch A. 2020. Sequence specificity analysis of the SETD2 protein lysine methyltransferase and discovery of a SETD2 super-substrate. Commun Biol. 3(1):511. doi: 10.1038/s42003-020-01223-6.
  • Schuhmacher MK, Kudithipudi S, Kusevic D, Weirich S, Jeltsch A. 2015. Activity and specificity of the human SUV39H2 protein lysine methyltransferase. Biochim Biophys Acta. 1849(1):55–63. doi: 10.1016/j.bbagrm.2014.11.005.
  • Seeler JS, Dejean A. 2017. SUMO and the robustness of cancer. Nat Rev Cancer. 17(3):184–197. doi: 10.1038/nrc.2016.143.
  • Senn HM, Thiel W. 2009. QM/MM methods for biomolecular systems. Angew Chem Int Ed Engl. 48(7):1198–1229. doi: 10.1002/anie.200802019.
  • Shilatifard A. 2012. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem. 81(1):65–95. doi: 10.1146/annurev-biochem-051710-134100.
  • Shinsky SA, Hu M, Vought VE, Ng SB, Bamshad MJ, Shendure J, Cosgrove MS. 2014. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes. J Mol Biol. 426(12):2283–2299. doi: 10.1016/j.jmb.2014.03.011.
  • Simon MD, Chu F, Racki LR, de la Cruz CC, Burlingame AL, Panning B, Narlikar GJ, Shokat KM. 2007. The site-specific installation of methyl-lysine analogs into recombinant histones. Cell. 128(5):1003–1012. doi: 10.1016/j.cell.2006.12.041.
  • Singh PR, Dadireddy V, Udupa S, Kalladi SM, Shee S, Khosla S, Rajmani RS, Singh A, Ramakumar S, Nagaraja V. 2023. The Mycobacterium tuberculosis methyltransferase Rv2067c manipulates host epigenetic programming to promote its own survival. Nat Commun. 14(1):8497. doi: 10.1038/s41467-023-43940-6.
  • Sirinupong N, Brunzelle J, Doko E, Yang Z. 2011. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3. J Mol Biol. 406(1):149–159. doi: 10.1016/j.jmb.2010.12.014.
  • Sirinupong N, Brunzelle J, Ye J, Pirzada A, Nico L, Yang Z. 2010. Crystal structure of cardiac-specific histone methyltransferase SmyD1 reveals unusual active site architecture. J Biol Chem. 285(52):40635–40644. doi: 10.1074/jbc.M110.168187.
  • Smith BC, Denu JM. 2009. Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta. 1789(1):45–57. doi: 10.1016/j.bbagrm.2008.06.005.
  • Smith E, Lin C, Shilatifard A. 2011. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 25(7):661–672. doi: 10.1101/gad.2015411.
  • Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. 2010. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 107(49):20980–20985. doi: 10.1073/pnas.1012525107.
  • Southall SM, Wong PS, Odho Z, Roe SM, Wilson JR. 2009. Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell. 33(2):181–191. doi: 10.1016/j.molcel.2008.12.029.
  • Spangler CJ, Yadav SP, Li D, Geil CN, Smith CB, Wang GG, Lee TH, McGinty RK. 2022. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding. Cell Rep. 38(7):110369. doi: 10.1016/j.celrep.2022.110369.
  • Spellmon N, Holcomb J, Trescott L, Sirinupong N, Yang Z. 2015. Structure and function of SET and MYND domain-containing proteins. Int J Mol Sci. 16(1):1406–1428. doi: 10.3390/ijms16011406.
  • Spellmon N, Sun X, Sirinupong N, Edwards B, Li C, Yang Z. 2015. Molecular Dynamics Simulation Reveals Correlated Inter-Lobe Motion in Protein Lysine Methyltransferase SMYD2. PLoS One. 10(12):e0145758. doi: 10.1371/journal.pone.0145758.
  • Stender JD, Pascual G, Liu W, Kaikkonen MU, Do K, Spann NJ, Boutros M, Perrimon N, Rosenfeld MG, Glass CK. 2012. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell. 48(1):28–38. doi: 10.1016/j.molcel.2012.07.020.
  • Stodola TJ, Chi Y-I, De Assuncao TM, Leverence EN, Tripathi S, Dsouza NR, Mathison AJ, Volkman BF, Smith BC, Lomberk G, et al. 2021. Computational modeling reveals key molecular properties and dynamic behavior of disruptor of telomeric silencing 1-like (DOT1L) and partnering complexes involved in leukemogenesis. Proteins. 90(1):282–298. doi: 10.1002/prot.26219.
  • Subtil-Rodríguez A, Vázquez-Chávez E, Ceballos-Chávez M, Rodríguez-Paredes M, Martín-Subero JI, Esteller M, Reyes JC. 2014. The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes. Nucleic Acids Res. 42(4):2185–2196. doi: 10.1093/nar/gkt1161.
  • Suh JL, Barnash KD, Abramyan TM, Li F, The J, Engelberg IA, Vedadi M, Brown PJ, Kireev DB, Arrowsmith CH, et al. 2019. Discovery of selective activators of PRC2 mutant EED-I363M. Sci Rep. 9(1):6524. doi: 10.1038/s41598-019-43005-z.
  • Sun J, Li Z, Yang N. 2021. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study. Int J Mol Sci. 22(13)
  • Sun J, Shi F, Yang N. 2019. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations. ACS Omega. 4(22):19573–19581. doi: 10.1021/acsomega.9b01842.
  • Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. 2001. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 276(27):25309–25317. doi: 10.1074/jbc.M101914200.
  • Tatton-Brown K, Douglas J, Coleman K, Baujat G, Cole TR, Das S, Horn D, Hughes HE, Temple IK, Faravelli F, et al. 2005. Genotype-phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet. 77(2):193–204. doi: 10.1086/432082.
  • Tisi D, Chiarparin E, Tamanini E, Pathuri P, Coyle JE, Hold A, Holding FP, Amin N, Martin ACL, Rich SJ, et al. 2016. Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin Derivatives. ACS Chem Biol. 11(11):3093–3105. doi: 10.1021/acschembio.6b00308.
  • Trievel RC, Beach BM, Dirk LMA, Houtz RL, Hurley JH. 2002. Structure and Catalytic Mechanism of a SET Domain Protein Methyltransferase. Cell. 111(1):91–103. doi: 10.1016/s0092-8674(02)01000-0.
  • Trievel RC, Flynn EM, Houtz RL, Hurley JH. 2003. Mechanism of multiple lysine methylation by the SET domain enzyme Rubisco LSMT. Nat Struct Biol. 10(7):545–552. doi: 10.1038/nsb946.
  • Trzesniak D, Kunz AP, van Gunsteren WF. 2007. A comparison of methods to compute the potential of mean force. Chemphyschem. 8(1):162–169. doi: 10.1002/cphc.200600527.
  • Ueda T, Sanada M, Matsui H, Yamasaki N, Honda ZI, Shih LY, Mori H, Inaba T, Ogawa S, Honda H. 2012. EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms. Leukemia. 26(12):2557–2560. doi: 10.1038/leu.2012.146.
  • Valencia-Sánchez MI, De Ioannes P, Wang M, Truong DM, Lee R, Armache J-P, Boeke JD, Armache K-J. 2021. Regulation of the Dot1 histone H3K79 methyltransferase by histone H4K16 acetylation. Science. 371(6527):eabc6663. doi: 10.1126/science.abc6663.
  • Valencia-Sánchez MI, De Ioannes P, Wang M, Vasilyev N, Chen R, Nudler E, Armache J-P, Armache K-J. 2019. Structural Basis of Dot1L Stimulation by Histone H2B Lysine 120 Ubiquitination. Mol Cell. 74(5):1010–1019.e6. e1016. doi: 10.1016/j.molcel.2019.03.029.
  • Van Aller GS, Graves AP, Elkins PA, Bonnette WG, McDevitt PJ, Zappacosta F, Annan RS, Dean TW, Su D-S, Carpenter CL, et al. 2016. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 24(5):774–781. doi: 10.1016/j.str.2016.03.010.
  • Van der Kamp MW, Mulholland AJ. 2013. Combined quantum mechanics/molecular mechanics (QM/MM) methods in computational enzymology. Biochemistry. 52(16):2708–2728. doi: 10.1021/bi400215w.
  • Voigt P, LeRoy G, Drury WJ, Zee BM, Son J, Beck DB, Young NL, Garcia BA, Reinberg D. 2012. Asymmetrically modified nucleosomes. Cell. 151(1):181–193. doi: 10.1016/j.cell.2012.09.002.
  • Vougiouklakis T, Bernard BJ, Nigam N, Burkitt K, Nakamura Y, Saloura V. 2020. Clinicopathologic significance of protein lysine methyltransferases in cancer. Clin Epigenetics. 12(1):146. doi: 10.1186/s13148-020-00897-3.
  • Waggoner DJ, Raca G, Welch K, Dempsey M, Anderes E, Ostrovnaya I, Alkhateeb A, Kamimura J, Matsumoto N, Schaeffer GB, et al. 2005. NSD1 analysis for Sotos syndrome: insights and perspectives from the clinical laboratory. Genet Med. 7(8):524–533. doi: 10.1097/01.GIM.0000178503.15559.d3.
  • Wang L, Li L, Zhang H, Luo X, Dai J, Zhou S, Gu J, Zhu J, Atadja P, Lu C, et al. 2011. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. J Biol Chem. 286(44):38725–38737. doi: 10.1074/jbc.M111.262410.
  • Wang S, Hu P, Zhang Y. 2007. Ab Initio Quantum Mechanical/Molecular Mechanical Molecular Dynamics Simulation of Enzyme Catalysis: The Case of Histone Lysine Methyltransferase SET7/9. J Phys Chem B. 111(14):3758–3764. doi: 10.1021/jp067147i.
  • Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, et al. 2018. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46(W1):W296–W303. doi: 10.1093/nar/gky427.
  • Weirich S, Jeltsch A. 2022. Specificity Analysis of Protein Methyltransferases and Discovery of Novel Substrates Using SPOT Peptide Arrays. In: Margueron R, Holoch D, editors. Histone Methyltransferases: Methods and Protocols. New York, NY: Springer US; p. 313–325.
  • Weirich S, Kudithipudi S, Jeltsch A. 2016. Specificity of the SUV4-20H1 and SUV4-20H2 protein lysine methyltransferases and methylation of novel substrates. J Mol Biol. 428(11):2344–2358. doi: 10.1016/j.jmb.2016.04.015.
  • Weirich S, Kudithipudi S, Jeltsch A. 2017. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex. Mol Oncol. 11(4):373–387. doi: 10.1002/1878-0261.12041.
  • Weirich S, Kudithipudi S, Kycia I, Jeltsch A. 2015. Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme. Clin Epigenetics. 7(1):36. doi: 10.1186/s13148-015-0075-3.
  • Weirich S, Schuhmacher MK, Kudithipudi S, Lungu C, Ferguson AD, Jeltsch A. 2020. Analysis of the Substrate Specificity of the SMYD2 Protein Lysine Methyltransferase and Discovery of Novel Non-Histone Substrates. Chembiochem. 21(1-2):256–264. doi: 10.1002/cbic.201900582.
  • Wiederstein JL, Nolte H, Günther S, Piller T, Baraldo M, Kostin S, Bloch W, Schindler N, Sandri M, Blaauw B, et al. 2018. Skeletal Muscle-Specific Methyltransferase METTL21C Trimethylates p97 and Regulates Autophagy-Associated Protein Breakdown. Cell Rep. 23(5):1342–1356. doi: 10.1016/j.celrep.2018.03.136.
  • Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, Blackburn GM, Gamblin SJ, Xiao B. 2002. Crystal Structure and Functional Analysis of the Histone Methyltransferase SET7/9. Cell. 111(1):105–115. doi: 10.1016/s0092-8674(02)00964-9.
  • Worden EJ, Hoffmann NA, Hicks CW, Wolberger C. 2019. Mechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L. Cell. 176(6):1490–1501.e12. e1412. doi: 10.1016/j.cell.2019.02.002.
  • Worden EJ, Zhang X, Wolberger C. 2020. Structural basis for COMPASS recognition of an H2B-ubiquitinated nucleosome. Elife. 9 doi: 10.7554/eLife.53199.
  • Wu H, Mathioudakis N, Diagouraga B, Dong A, Dombrovski L, Baudat F, Cusack S, de Massy B, Kadlec J. 2013. Molecular basis for the regulation of the H3K4 methyltransferase activity of PRDM9. Cell Rep. 5(1):13–20. doi: 10.1016/j.celrep.2013.08.035.
  • Wu H, Min J, Lunin VV, Antoshenko T, Dombrovski L, Zeng H, Allali-Hassani A, Campagna-Slater V, Vedadi M, Arrowsmith CH, et al. 2010. Structural biology of human H3K9 methyltransferases. PLoS One. 5(1):e8570. doi: 10.1371/journal.pone.0008570.
  • Wu J, Cheung T, Grande C, Ferguson AD, Zhu X, Theriault K, Code E, Birr C, Keen N, Chen H. 2011. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. Biochemistry. 50(29):6488–6497. doi: 10.1021/bi200725p.
  • Wu K, Niu C, Liu H, Fu L. 2023. Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation (Review). Int J Oncol. 62(5) doi: 10.3892/ijo.2023.5510.
  • Xiao B, Jing C, Kelly G, Walker PA, Muskett FW, Frenkiel TA, Martin SR, Sarma K, Reinberg D, Gamblin SJ, et al. 2005. Specificity and mechanism of the histone methyltransferase Pr-Set7. Genes Dev. 19(12):1444–1454. doi: 10.1101/gad.1315905.
  • Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ. 2003. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 421(6923):652–656. doi: 10.1038/nature01378.
  • Xu S, Aguilar A, Huang L, Xu T, Zheng K, McEachern D, Przybranowski S, Foster C, Zawacki K, Liu Z, et al. 2020. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity. J Med Chem. 63(9):4997–5010. doi: 10.1021/acs.jmedchem.0c00547.
  • Xu S, Wu J, Sun B, Zhong C, Ding J. 2011. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding. Nucleic Acids Res. 39(10):4438–4449. doi: 10.1093/nar/gkr019.
  • Xu S, Zhong C, Zhang T, Ding J. 2011. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins. J Mol Cell Biol. 3(5):293–300. doi: 10.1093/jmcb/mjr015.
  • Xue H, Yao T, Cao M, Zhu G, Li Y, Yuan G, Chen Y, Lei M, Huang J. 2019. Structural basis of nucleosome recognition and modification by MLL methyltransferases. Nature. 573(7774):445–449. doi: 10.1038/s41586-019-1528-1.
  • Yang S, Zheng X, Lu C, Li GM, Allis CD, Li H. 2016. Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase. Genes Dev. 30(14):1611–1616. doi: 10.1101/gad.284323.116.
  • Yang T, Zhang W, Cheng J, Nie Y, Xin Q, Yuan S, Dou Y. 2019. Formation Mechanism of Ion Channel in Channelrhodopsin-2: Molecular Dynamics Simulation and Steering Molecular Dynamics Simulations. Int J Mol Sci. 20(15)
  • Yao J, Chu Y, An R, Guo H. 2012. Understanding product specificity of protein lysine methyltransferases from QM/MM molecular dynamics and free energy simulations: the effects of mutation on SET7/9 beyond the Tyr/Phe switch. J Chem Inf Model. 52(2):449–456. doi: 10.1021/ci200364m.
  • Yao Y, Chen P, Diao J, Cheng G, Deng L, Anglin JL, Prasad BV, Song Y. 2011. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc. 133(42):16746–16749. doi: 10.1021/ja206312b.
  • Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, et al. 2011. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 117(8):2451–2459. doi: 10.1182/blood-2010-11-321208.
  • Yi Y, Ge S. 2022. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol Oncol. 15(1):35. doi: 10.1186/s13045-022-01251-1.
  • Yoneda S, Saito T, Nakajima D, Watanabe G. 2021. Potential of mean force and umbrella sampling simulation for the transport of 5-oxazolidinone in heterotetrameric sarcosine oxidase. Proteins. 89(7):811–818. doi: 10.1002/prot.26060.
  • You W, Tang Z, Chang CA. 2019. Potential Mean Force from Umbrella Sampling Simulations: What Can We Learn and What Is Missed? J Chem Theory Comput. 15(4):2433–2443. doi: 10.1021/acs.jctc.8b01142.
  • Yu H, Dalby PA. 2020. A beginner’s guide to molecular dynamics simulations and the identification of cross-correlation networks for enzyme engineering. Methods Enzymol. 643:15–49. doi: 10.1016/bs.mie.2020.04.020.
  • Yue L, Du J, Ye F, Chen Z, Li L, Lian F, Zhang B, Zhang Y, Jiang H, Chen K, et al. 2016. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide. Org Biomol Chem. 14(36):8503–8519. doi: 10.1039/c6ob01248e.
  • Zhang R, Li X, Liang Z, Zhu K, Lu J, Kong X, Ouyang S, Li L, Zheng YG, Luo C. 2013. Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1. PLoS One. 8(8):e72424. doi: 10.1371/journal.pone.0072424.
  • Zhang X, Bruice T. 2007a. Catalytic Mechanism and Product Specificity of Rubisco Large Subunit Methyltransferase: QM/MM and MD Investigations. Biochemistry. 46(18):5505–5514. doi: 10.1021/bi700119p.
  • Zhang X, Bruice T. 2007b. Histone Lysine Methyltransferase SET7/9: Formation of a Water Channel Precedes Each Methyl Transfer. Biochemsitry. 46(51):14838–14844. doi: 10.1021/bi7014579.
  • Zhang X, Bruice T. 2007c. A Quantum Mechanics/Molecular Mechanics Study of the Catalytic Mechanism and Product Specificity of Viral Histone Lysine Methyltransferase. Biochemistry. 46(34):9743–9751. doi: 10.1021/bi700515q.
  • Zhang X, Bruice T. 2008a. Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases. PNAS. 105
  • Zhang X, Bruice T. 2008b. Mechanism of Product Specificity of AdoMet Methylation Catalyzed by Lysine Methyltransferases: Transcriptional Factor p53 Methylation by Histone Lysine Methyltransferase SET7/9. Biochemistry. 47(9):2743–2748. doi: 10.1021/bi702370p.
  • Zhang X, Bruice T. 2008c. Product Specificity and Mechanism of Protein Lysine Methyltransferases: Insights from the Histone Lysine Methyltransferase SET8. Biochemistry. 47(25):6671–6677. doi: 10.1021/bi800244s.
  • Zhang X, Huang Y, Shi X. 2015. Emerging roles of lysine methylation on non-histone proteins. Cell Mol Life Sci. 72(22):4257–4272. doi: 10.1007/s00018-015-2001-4.
  • Zhang X, Tamaru H, Khan SI, Horton JR, Keefe LJ, Selker EU, Chen X. 2002. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. Cell. 111(1):117–127. doi: 10.1016/s0092-8674(02)00999-6.
  • Zhang X, Yang Z, Khan SI, Horton JR, Tamaru H, Selker EU, Cheng X. 2003. Structural basis for the product specificity of histone lysine methyltransferases. Mol Cell. 12(1):177–185. doi: 10.1016/s1097-2765(03)00224-7.
  • Zhang Y, Alshammari E, Sobota J, Yang A, Li C, Yang Z. 2022. Unique SMYD5 Structure Revealed by AlphaFold Correlates with Its Functional Divergence. Biomolecules. 12(6) doi: 10.3390/biom12060783.
  • Zhang Y, Hayden S, Spellmon N, Xue W, Martin K, Muzzarelli K, Kovari L, Yang Z. 2021. Sperm chromatin-condensing protamine enhances SMYD5 thermal stability. Biochem Biophys Res Commun. 550:1–7. doi: 10.1016/j.bbrc.2021.02.073.
  • Zhang Y, Shan CM, Wang J, Bao K, Tong L, Jia S. 2017. Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation. Sci Rep. 7(1):43906. doi: 10.1038/srep43906.
  • Zhao YY, Deng H, Rahman A, Xu XL, Qian P, Guo H. 2022. Computational Study of Methionine Methylation Process Catalyzed by SETD3. Interdiscip Sci. 14(4):929–936. doi: 10.1007/s12539-022-00516-0.
  • Zheng W, Ibáñez G, Wu H, Blum G, Zeng H, Dong A, Li F, Hajian T, Allali-Hassani A, Amaya MF, et al. 2012. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc. 134(43):18004–18014. doi: 10.1021/ja307060p.
  • Zhou H, Liu L, Huang J, Bernard D, Karatas H, Navarro A, Lei M, Wang S. 2013. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J Med Chem. 56(3):1113–1123. doi: 10.1021/jm3015298.
  • Zhou R, Xie Y, Hu H, Hu G, Patel VS, Zhang J, Yu K, Huang Y, Jiang H, Liang Z, et al. 2015. Molecular Mechanism underlying PRMT1 Dimerization for SAM Binding and Methylase Activity. J Chem Inf Model. 55(12):2623–2632. doi: 10.1021/acs.jcim.5b00454.
  • Zoabi M, Zhang L, Li TM, Elias JE, Carlson SM, Gozani O. 2020. Methyltransferase-like 21C (METTL21C) methylates alanine tRNA synthetase at Lys-943 in muscle tissue. J Biol Chem. 295(33):11822–11832. doi: 10.1074/jbc.RA120.014505.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.